Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business clinical trial failure

Sionna Therapeutics Phase 2a Trial Failure

Analysis based on 30 articles · First reported Aug 12, 2026 · Last updated Sep 03, 2026

Sentiment
-80
Attention
4
Articles
30
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The failed trial wiped out over 90% of Sionna's market value in a single session, severely impacting shareholders and triggering multiple securities investigations. The event highlights the high-risk nature of clinical-stage biopharmaceutical investments and may lead to legal liabilities for the company.

Biopharmaceuticals Healthcare

On August 10, 2026, Sionna Therapeutics announced that its Phase 2a PreciSION CF trial of SION-719, an investigational cystic fibrosis treatment, failed to achieve its key activity endpoint of sweat chloride reduction when added to standard-of-care Trikafta. The placebo-adjusted sweat chloride change was -1.0 mmol/L with a p-value of 0.7, and the company stated it would not advance SION-719 as an add-on therapy. Following the disclosure, Sionna's stock price plummeted 91.18%, falling $46.54 to close at $4.50 per share, erasing approximately 92% of the company's market value. The company reported $268.3 million in cash and equivalents as of June 30, 2026, with a Q2 net loss of $29.9 million and runway into 2028. In response, multiple law firms, including Pomerantz LLP, Levi & Korsinsky, and Robbins Geller Rudman & Dowd LLP, launched investigations into potential securities fraud or unlawful business practices by Sionna and certain officers and directors, focusing on statements made before the trial results were disclosed.

100 Sionna Therapeutics reported failed trial
100 Sionna Therapeutics lost 90% market value
80 Levi & Korsinsky launched investigation Sionna Therapeutics
80 Pomerantz LLP launched investigation Sionna Therapeutics
priv
Sionna Therapeutics is the central entity; its Phase 2a trial failure caused a 91% stock price collapse and triggered securities investigations. The company faces potential legal claims and reputational damage.
Importance 100.0 Sentiment -95.0
priv
Pomerantz LLP launched an investigation into potential securities fraud by Sionna, representing investors who suffered losses.
Importance 40.0 Sentiment 0.0
priv
Levi & Korsinsky is investigating potential securities law violations on behalf of SION investors, providing a channel for affected shareholders to seek recovery.
Importance 40.0 Sentiment 0.0
priv
Robbins Geller Rudman & Dowd LLP is investigating potential federal securities law violations involving Sionna, encouraging investors and witnesses to come forward.
Importance 40.0 Sentiment 0.0
per
Joseph E. Levi is the lead attorney at Levi & Korsinsky handling the Sionna investigation, acting as the primary contact for investor inquiries.
Importance 30.0 Sentiment 10.0
cnt
The investigations are conducted under U.S. federal securities laws, and the event affects U.S. investors and the biopharmaceutical regulatory environment.
Importance 20.0 Sentiment 0.0
exch
Nasdaq is the exchange where Sionna's stock is listed; the event led to a dramatic decline in SION's price on this exchange.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.